Vestor Capital LLC Sells 24,349 Shares of AbbVie Inc. (NYSE:ABBV)

Vestor Capital LLC trimmed its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 63.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,734 shares of the company's stock after selling 24,349 shares during the period. Vestor Capital LLC's holdings in AbbVie were worth $2,878,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Quantbot Technologies LP increased its holdings in shares of AbbVie by 35.8% in the fourth quarter. Quantbot Technologies LP now owns 1,047 shares of the company's stock worth $186,000 after acquiring an additional 276 shares in the last quarter. Hillsdale Investment Management Inc. increased its holdings in shares of AbbVie by 9.6% in the fourth quarter. Hillsdale Investment Management Inc. now owns 2,628 shares of the company's stock worth $467,000 after acquiring an additional 230 shares in the last quarter. Finally, CoreFirst Bank & Trust bought a new stake in shares of AbbVie in the fourth quarter worth about $717,000. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research reports. BNP Paribas upgraded AbbVie to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald began coverage on AbbVie in a report on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 price target for the company. Bank of America lifted their price target on AbbVie to $204.00 and gave the stock a "hold" rating in a report on Monday, June 9th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $194.00 price objective on shares of AbbVie in a report on Tuesday, April 8th. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $211.29.

AbbVie Trading Down 0.3%

Shares of NYSE ABBV traded down $0.61 during trading on Friday, reaching $190.22. The company had a trading volume of 3,786,155 shares, compared to its average volume of 6,461,288. The stock has a market cap of $336.00 billion, a P/E ratio of 80.94, a PEG ratio of 1.27 and a beta of 0.48. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The company's fifty day moving average price is $187.62 and its 200-day moving average price is $189.70. AbbVie Inc. has a 12 month low of $163.81 and a 12 month high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The company had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. During the same period in the previous year, the business earned $2.31 EPS. The firm's revenue was up 8.4% compared to the same quarter last year. As a group, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie's dividend payout ratio (DPR) is currently 279.15%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.